Breaking News Instant updates and real-time market news.

RGLS

Regulus

$1.40

-0.025 (-1.75%)

, AZN

AstraZeneca

$34.17

-0.65 (-1.87%)

07:05
06/12/17
06/12
07:05
06/12/17
07:05

Regulus announces pipeline updates, expansions

Regulus Therapeutics (RGLS) announced updates to its pre-clinical and clinical development programs. "We are squarely focused on taking the steps necessary to advance our pipeline and continue building shareholder value. To that end, we recognize that we must be disciplined in our investment choices and focus our resources and capital on our most promising discovery and development programs, including the application of important development, regulatory and commercial considerations," said Jay Hagan, President and CEO of Regulus. "MicroRNA therapeutics have the potential to become an important new class of drugs with broad therapeutic application. Regulus' focus will be in diseases with significant unmet medical need in organs to which we have been able to preferentially deliver oligonucleotide therapeutics effectively, such as the liver and kidney." Initiation of the Phase II clinical programs for RG-012 for the treatment of Alport syndrome is on track as planned. The Company announced today that it plans to discontinue clinical development of RG-101 upon completion of the one remaining clinical study, which is expected to occur in July 2017. Comprehensive pre-clinical investigation and thorough evaluation of the clinical data from RG-101 has led to the identification of a bilirubin transport mechanism as the likely cause for the cases of hyperbilirubinemia in the RG-101 program. The IND for RGLS4326 is on track for filing by year end 2017. RGLS5040 (anti-miR-27) for cholestatic disease: RGLS5040, an unconjugated inhibitor of microRNA27, has been discontinued based on a positioning of the compound with respect to the competitive landscape coupled with the results from repeat pharmacology studies as part of IND-enabling work. Separately, AstraZeneca (AZN) informed the Company that it intends to terminate the clinical development program for AZD4076(RG-125) for the treatment of NASH in Type 2 Diabetes/Pre-diabetes. Pursuant to the terms of the licensing agreement, AstraZeneca's rights with respect to AZD4076(RG-125) will revert to Regulus when the termination becomes effective in twelve months. AZD4076(RG-125) was jointly identified and selected as a clinical candidate in April 2015 by AstraZeneca under the companies' strategic alliance to discover, develop and commercialize microRNA therapeutics.

RGLS

Regulus

$1.40

-0.025 (-1.75%)

AZN

AstraZeneca

$34.17

-0.65 (-1.87%)

  • 26

    Jun

RGLS Regulus
$1.40

-0.025 (-1.75%)

12/16/16
CANT
12/16/16
INITIATION
Target $11
CANT
Overweight
Regulus initiated with an Overweight at Cantor
Cantor Fitzgerald analyst William Tanner started Regulus Therapeutics with an Overweight rating and $11 price target.
01/30/17
WELS
01/30/17
DOWNGRADE
WELS
Market Perform
Regulus downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough downgraded Regulus Therapeutics to Market Perform citing the continued clinical hold on RG-101 for the treatment of hepatitis C. The analyst is not optimistic that FDA concerns will be addressed. He lowered his price target range for the shares to $1.00-$2.00 from $6.75-$8.00.
01/30/17
NEED
01/30/17
DOWNGRADE
NEED
Hold
Regulus downgraded to Hold from Buy at Needham
01/30/17
01/30/17
DOWNGRADE

Hold
Regulus downgraded to Hold at Needham
As previously reported, Needham analyst Alan Carr downgraded Regulus to Hold from Buy due to absence of near-term material clinical milestones. The analyst believes opportunity for the company to capture value in HCV is fading given growing number of effective once-daily oral options.
AZN AstraZeneca
$34.17

-0.65 (-1.87%)

05/17/17
JPMS
05/17/17
UPGRADE
Target $72
JPMS
Overweight
Clovis upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov upgraded Clovis Oncology (CLVS) to Overweight and raised his price target for the shares to $72 from $58. The stock closed yesterday up 2%, or $1.05, to $49.56. The shares are down 35% over the last two months for "no clear fundamental reason," Kasimov tells investors in a research note. The analyst is "increasingly comfortable" recommending Clovis ahead of its Phase 3 study evaluating Rubraca in maintenance ovarian cancer now that more PARP class data has emerged. He has not seen "convincing evidence" that there is a clear efficacy difference between Clovis' rucaparib, Tesaro's (TSRO) niraparib and AstraZeneca's (AZN) olaparib.
06/01/17
RHCO
06/01/17
NO CHANGE
RHCO
SunTrust sees $240/share takeout price for Tesaro
After the Wall Street Journal reported yesterday that Tesaro (TSRO) is exploring a sale, albeit with "modest" interest, SunTrust analyst Peter Lawson says his analysis suggests a $240 per share takeout price for the company. Tesaro closed yesterday up $5.88, or 4%, to $149.31. Acquisitions in the PARP inhibitor space are more likely to happen after Clovis Oncology's (CLVS) ARIEL 3 data at the end of June, as the readout will provide a more apples-to-apples comparison to Tesaro and AstraZeneca (AZN), Lawson tells investors in a research note. His "bull case" points to a $286 per share price for Tesaro and $92 per share price for Clovis. Lawson has Buy ratings on both names. JPMorgan's Cory Kasimov this morning said he likes the setup for Clovis shares into the late June data announcement.
06/05/17
PIPR
06/05/17
NO CHANGE
PIPR
Piper views AstraZeneca, J&J as ASCO standouts
The standouts at ASCO over the weekend were the "compelling results" presented on Johnson & Johnson's (JNJ) Zytiga from the Latitude study in prostate cancer and AstraZeneca's (AZN) Lynparza in the OlympiAD trial in BRCA mutant breast cancer, Piper Jaffray analyst Richard Purkiss tells investors in a research note. In lung cancer, Merck's (MRK) updated data in KN021G "appears more promising" than Bristol-Myers' (BMY) updated data in CM012, the analyst adds. Purkiss believes, however, that relative to recent ASCOs, the data "so far in totality is underwhelming."
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).

TODAY'S FREE FLY STORIES

CRVS

Corvus Pharmaceuticals

$13.00

1.13 (9.52%)

20:37
08/23/17
08/23
20:37
08/23/17
20:37
Upgrade
Corvus Pharmaceuticals rating change  »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$56.28

0.33 (0.59%)

20:35
08/23/17
08/23
20:35
08/23/17
20:35
Upgrade
Portola Pharmaceuticals rating change  »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 02

    Feb

TEVA

Teva

$16.49

-0.52 (-3.06%)

20:35
08/23/17
08/23
20:35
08/23/17
20:35
Downgrade
Teva rating change  »

Teva downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 27

    Sep

LOW

Lowe's

$73.01

-2.81 (-3.71%)

20:33
08/23/17
08/23
20:33
08/23/17
20:33
Downgrade
Lowe's rating change  »

Lowe's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 21

    Nov

HRL

Hormel Foods

$33.92

-0.46 (-1.34%)

, DLTR

Dollar Tree

$74.32

-0.63 (-0.84%)

20:25
08/23/17
08/23
20:25
08/23/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

HRL

Hormel Foods

$33.92

-0.46 (-1.34%)

DLTR

Dollar Tree

$74.32

-0.63 (-0.84%)

SJM

J.M. Smucker

$118.85

-1.01 (-0.84%)

TIF

Tiffany

$88.72

0.22 (0.25%)

TTC

Toro Company

$69.02

-1.76 (-2.49%)

SPLS

Staples

$10.18

-0.02 (-0.20%)

BURL

Burlington Stores

$84.95

-1.43 (-1.66%)

MIK

Michaels

$19.61

0.02 (0.10%)

SIG

Signet Jewelers

$51.89

-0.26 (-0.50%)

ANF

Abercrombie & Fitch

$9.61

0.46 (5.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 24

    Aug

  • 05

    Sep

  • 06

    Sep

  • 03

    Oct

  • 04

    Oct

HSY

Hershey

$107.44

0.34 (0.32%)

19:16
08/23/17
08/23
19:16
08/23/17
19:16
Hot Stocks
Hershey Company to acquire 1.5M common shares from Hershey Trust »

The Hershey Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSADY

MS&AD Insurance

$17.08

-0.085 (-0.50%)

19:07
08/23/17
08/23
19:07
08/23/17
19:07
Hot Stocks
MS&AD Insurance to acquire First Capital Insurance in $1.6B deal »

Fairfax Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$169.00

-1.07 (-0.63%)

18:46
08/23/17
08/23
18:46
08/23/17
18:46
Hot Stocks
Amgen: Lancet Oncology publishes survival analysis from KYPROLIS Phase 3 trial »

Amgen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Sep

  • 11

    Sep

  • 14

    Sep

  • 02

    Dec

  • 03

    Feb

  • 17

    May

GE

General Electric

$24.39

-0.21 (-0.85%)

, ABB

ABB

$23.13

-0.01 (-0.04%)

18:39
08/23/17
08/23
18:39
08/23/17
18:39
Periodicals
GE resumes talks with ABB over industrial solutions deal, Reuters reports »

General Electric (GE) has…

GE

General Electric

$24.39

-0.21 (-0.85%)

ABB

ABB

$23.13

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 11

    Sep

  • 02

    Oct

LZB

La-Z-Boy

$24.95

-6.3 (-20.16%)

, AMZN

Amazon.com

$958.00

-8.9 (-0.92%)

18:17
08/23/17
08/23
18:17
08/23/17
18:17
Periodicals
La-Z-Boy in talks with Amazon over youth shopper outreach, MarketWatch reports »

La-Z-Boy (LZB) is in…

LZB

La-Z-Boy

$24.95

-6.3 (-20.16%)

AMZN

Amazon.com

$958.00

-8.9 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 24

    Aug

  • 29

    Aug

VLKAY

Volkswagen

$30.67

0.19 (0.62%)

18:14
08/23/17
08/23
18:14
08/23/17
18:14
Periodicals
VW to launch two-tone compact SUV, Bloomberg says »

Volkswagen plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$10.71

0.06 (0.56%)

18:01
08/23/17
08/23
18:01
08/23/17
18:01
Hot Stocks
Ford names Jason Luo as chairman, CEO of Ford China »

Ford announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$238.09

-1.66 (-0.69%)

, LMT

Lockheed Martin

$302.84

-1.96 (-0.64%)

17:47
08/23/17
08/23
17:47
08/23/17
17:47
Periodicals
Boeing 'disappointed' company not chosen for cruise missile deal, Bloomberg says »

Lockheed (LMT), Raytheon…

BA

Boeing

$238.09

-1.66 (-0.69%)

LMT

Lockheed Martin

$302.84

-1.96 (-0.64%)

RTN

Raytheon

$178.19

-1.03 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

HBM

Hudbay Minerals

$8.50

0.2 (2.41%)

17:44
08/23/17
08/23
17:44
08/23/17
17:44
Hot Stocks
Hudbay Minerals acquires 10.76M common shares of Mason Resources »

Hudbay Minerals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

17:32
08/23/17
08/23
17:32
08/23/17
17:32
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. sees Q4 PC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

GES

Guess

$12.48

0.11 (0.89%)

, TLYS

Tilly's

$9.60

0.88 (10.09%)

17:29
08/23/17
08/23
17:29
08/23/17
17:29
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Guess…

GES

Guess

$12.48

0.11 (0.89%)

TLYS

Tilly's

$9.60

0.88 (10.09%)

WSM

Williams-Sonoma

$43.40

0.55 (1.28%)

PVH

PVH Corp.

$120.04

-0.28 (-0.23%)

YUME

YuMe

$5.15

0.09 (1.78%)

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

HEI

Heico

$81.11

-0.95 (-1.16%)

GBT

Global Blood Therapeutics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 23

    Aug

  • 24

    Aug

  • 24

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

  • 06

    Sep

  • 06

    Sep

  • 07

    Sep

  • 07

    Sep

  • 08

    Sep

  • 11

    Sep

  • 28

    Sep

MATX

Matson

$24.02

0.24 (1.01%)

17:28
08/23/17
08/23
17:28
08/23/17
17:28
Hot Stocks
Matson upgrading its Honolulu terminal »

Matson announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$33.90

0.78 (2.36%)

17:24
08/23/17
08/23
17:24
08/23/17
17:24
Syndicate
Breaking Syndicate news story on Tactile Systems »

Tactile Systems files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$33.90

0.78 (2.36%)

17:23
08/23/17
08/23
17:23
08/23/17
17:23
Syndicate
Breaking Syndicate news story on Tactile Systems »

Tactile Systems files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIVI

Civitas Solutions

$18.30

-0.1 (-0.54%)

17:21
08/23/17
08/23
17:21
08/23/17
17:21
Recommendations
Civitas Solutions analyst commentary  »

Civitas announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$179.28

-1.39 (-0.77%)

17:20
08/23/17
08/23
17:20
08/23/17
17:20
Hot Stocks
L3 Technologies awarded $172.9M government contract modification »

L-3 Communications Vertex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$238.08

-1.67 (-0.70%)

17:19
08/23/17
08/23
17:19
08/23/17
17:19
Hot Stocks
Boeing awarded $222.5M government contract modification »

The Boeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$178.19

-1.03 (-0.57%)

17:18
08/23/17
08/23
17:18
08/23/17
17:18
Hot Stocks
Raytheon awarded approximately $900M government contract »

Raytheon Co., Tucson,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$302.84

-1.96 (-0.64%)

17:17
08/23/17
08/23
17:17
08/23/17
17:17
Hot Stocks
Lockheed Martin awarded approximately $900M government contract »

Lockheed Martin Corp.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

, SSNLF

Samsung

$2,020.00

-10 (-0.49%)

17:11
08/23/17
08/23
17:11
08/23/17
17:11
Hot Stocks
HP Inc. sees Samsung deal closing in Q4 »

HP Inc. (HPQ) said it saw…

HPQ

HP Inc.

$18.86

-0.16 (-0.84%)

SSNLF

Samsung

$2,020.00

-10 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 29

    Aug

  • 29

    Aug

  • 31

    Aug

  • 01

    Sep

  • 06

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.